iVoice\'s Thomas Pharmaceuticals Ltd. Subsidiary To Launch New Version of Acid + All(TM) At National Association of Chain Drug Stores\' Annual Marketplace; Showcase New Black Cherry Flavor to Buyers
MATAWAN, N.J.--(BUSINESS WIRE)--June 15, 2006--Thomas Pharmaceuticals Ltd, a wholly owned subsidiary of iVoice, Inc. (OTCBB:IVOI), announced today that it will present to senior industry executives at the National Association of Chain Drug Stores\' (NACDS) Annual Marketplace Conference scheduled from June 23-27th in San Diego. Thomas Pharmaceuticals will be showcasing the launch of the New Black Cherry flavor of Acid + All(TM) and unveiling two new product lines targeted at today\'s affluent baby boomer market. The presentation will include a sleekly packaged, high-end antacid tablet, Acid + All(TM) , which is changing the over-the-counter pharmaceutical category by offering a highly effective pharmaceutical product within an attractive packaging. Consumers are now able to find Acid + All(TM)\'s chic blue and white tin at their local drugstores.
NACDS is the industry\'s largest trade show attended by 200 retailers, representing 100,000 stores and $540 billion in buying power. At the conference, Thomas\' management will meet with senior executives and division and category managers responsible for bringing new products to drugstore customers. "This is a tremendous opportunity to present Acid + All(TM), the first product in the Thomas Pharmaceuticals Ltd. family of innovative over the counter healthcare products to decision makers and to begin the purchase order process," said Mr. Thomas, President and Founder of Thomas Pharmaceuticals Ltd.
Acid + All(TM), the calcium enriched, spearmint-flavored, sugar free tablets that soothe heartburn, acid indigestion and gas is available at independent pharmacies, major drug chains and online retailers or by calling toll-free at 1-888-922-1959. Acid + All(TM) will be available in a sleek, 32-count pillbox and will retail for approximately $3.89. Thomas Pharmaceutical plans to introduce Acid + All(TM) line extensions later this year along with other new over-the-counter products. For more information about Acid + All(TM) go to www.acidall.com.
About Thomas Pharmaceuticals Ltd:
Thomas Pharmaceuticals Ltd., based in New York, NY, develops and markets over the counter non-prescription healthcare products. The company focuses on high-end, branded consumables. Its first product, Acid + All(TM), is a calcium-enriched, sugar free, anti-gas antacid.
About iVoice, Inc:
iVoice has determined that the best way to create shareholder value, separate and apart from the operating performance of iVoice, is to implement new business opportunities by distributing shares of spin-offs to the company\'s shareholders. The common stock distributions are part of a broader strategy relating to the transition of iVoice into a company focused on the development and licensing of proprietary technologies. We also continue to search for potential merger candidates with or without compatible technology and products, which management feels may make financing more appealing to potential investors.
Certain information included in this press release, may contain forward-looking statements about our current and expected performance trends, growth plans, business goals and other matters. These statements may be contained in our filings with the Securities and Exchange Commission, in our press releases, in other written communications, and in oral statements made by or with the approval of one of our authorized officers. Information set forth in this press release contains various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation Reform Act of 1995 (the "Act" provides certain "safe harbor" provisions for forward-looking statements. The reader is cautioned that such forward-looking statements are based on information available at the time and/or management\'s good faith belief with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the statements. Forward-looking statements speak only as of the date the statement was made. We assume no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information. Forward-looking statements are typically identified by the use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "should," "will," and similar words, although some forward-looking statements are expressed differently. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
For more information on iVoice, please visit http://www.ivoice.com or http://www.thomaspharmaceuticals.com/
CONTACT: iVoice, Inc. Investor Relations Dolores Serafin, 732-441-7700 investors@ivoice.comhttp://www.ivoice.com or CEOcast, Inc. for iVoice Andrew Hellman, 212-732-4300 adhellman@ceocast.com
SOURCE: iVoice, Inc.
|